Effect of the mucoactive drug nacystelyn on the respiratory burst of human blood polymorphonuclear neutrophils

Pulmonary Pharmacology and Therapeutics

Volumn 10, Issue 5-6, 1997, Pages 287-292

  Nagy, A M ^a,b,d   Vanderbist, F ^b   Parij, N ^a   Maes, P ^b   Fondu, P ^c   Neve J ^a  

^a PHARMACEUTICAL INSTITUTE   (Belgium)

^b SMB Galephar Pharmaceuticals   (Belgium)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Captopril; N acetylcysteine; Nacystelyn; Polymorphonuclear neutrophils; Respiratory burst

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CAPTOPRIL; HYDROXYL RADICAL; LUCIGENIN; LUMINOL; NACYSTELYN; RADICAL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ZYMOSAN;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL ACTIVATION; CHEMOLUMINESCENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLAMMATION; LUNG DISEASE; LUNG INJURY; NEUTROPHIL; NORMAL HUMAN; PHAGOCYTE; PRIORITY JOURNAL; RESPIRATORY BURST;

EID: 0031260625     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1998.0106     Document Type: Article

References (40)

1. 1. Babior B M. Oxygen-dependent microbial killing of phagocytes. N Engl J Med 1978; 298: 659-721.
2. 2. Austen K F. Homeostasis of effector systems which can also be recruited for immunologic reactions. J Immun 1978; 121: 793-805.
3. 3. Halliwell B. Production of superoxide, hydrogen peroxide and hydroxyl radicals by phagocytic cells: a cause of chronic inflammatory disease. Cell Biol Int Rep 1982; 6: 529-542.
4. 4. Grisham M B. Oxidants and free radicals in inflammatory bowel disease. The Lancet 1994; 344: 859-863.
5. 5. Carp H, Miller F, Hoidal J R, Janoff A. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decrease elastase inhibitory capacity. Proc Natl Acad Sci USA 1982; 79: 2041-2045.
6. 6. Baldwin S R, Grum C M, Boxer L A, Simon R H, Ketan L H, Deuvall L J. Oxidant activity in expired breath of patients with adult respiratory syndrome. The Lancet 1986; 1 (8471): 11-13.
7. 7. Cross C E, van der Vliet A, O'Neill C A, Eiserich J P. Reactive oxygen species and the lung. The Lancet 1994; 344: 930-933.
8. 8. Vachier I, Chanez P, Le Doucen C, Damon M, Descomps B, Godard P. Enhancement of reactive oxygen species formation in stable and unstable asthmatics patients. Eur Respir J 1994; 7: 1585-1592.
9. 9. Wallaert B, Gressier B, Marquette C H, Gosset P, Remy-Jardin M, Mizon J, Tonnel A B. Inactivation of alpha-1 proteinase inhibitor by alveolar inflammatory cells from smoking patients with or without emphysema. Am Rev Respir Dis 1993; 147: 1537-1543.
10. 10. King M, Tomkiewicz R P, Coffiner M, Maes P. A comparison of new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog. Pulmonary Pharmacol 1996; 8: 259-265.
11. 11. Mira M L, Silva M M, Queiroz M J, Manso C F. Angiotensin converting enzyme inhibitors as oxygen free radical scavengers. Free Rad Res Commun 1993; 19: 173-181.
12. 12. Felix K, Pairet M, Zimmermann R. The antioxidative activity of the mucoregulatory agents: ambroxol, bromhexine and N-acetyl-L-cysteine. A pulse radiolysis study. Life Sciences 1996; 59: 1141-1147.
13. 13. Aruoma O I, Halliwell B, Hoey B M, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide and hypochlorous acid. Free Rad Biol Med 1989; 6: 593-597.
14. 14. Vanderbist F, Maes P, Nève J. In vitro comparative assessment of the antioxidant activity of nacystelyn against three reactive oxygen species. Arzneim-Forsch Drug Res 1996; 46: 783-788.
15. 15. Gillissen A, Jaworska M, Orth M, Coffiner M, Maes P, App E M, Cantin A M, Schultze-Werninghaus G. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir Med 1997; 91: 159-168.
16. 16. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. J Clin Lab Invest 1968; 21: 77-89.
17. 17. Rao P S, Luber J M Jr, Milinowicz J, Lolezari P, Mueller H S. Specificity of oxygen radical scavengers and assessment of free radical scavenger efficiency using luminol-enhanced chemiluminescence. Biochem Biophys Res Commun 1988; 150: 39-44.
18. 2 produced by human neutrophils during the respiratory burst. Anal Biochem 1987; 165: 371-378.
19. 19. Allen R C, Loose L D. Phagocytic activation of luminol-dependent chemiluminescence in rabbit alveolar and peritoneal macrophages. Biochem Biophys Res Commun 1976; 96: 245-252.
20. 4 and N-formyl-methionyl-leucyl-phenylalanine. Photochem Photobiol 1989; 49: 217-223.
21. 21. Vilim V, Wilhelm J. What do we measure by a luminol-dependent chemiluminescence of phagocytes? Free Radic Biol Med 1989; 6: 623-629.
22. 22. Gyllenhammar H. Lucigenin chemiluminescence in the assessment of neutrophil superoxide production. J Immunol Methods 1987; 97: 209-213.
23. 23. Tomkiewicz R P, App E M, Coffiner M, Fossion J, Maes P, King M. Mucolytic treatment with N-acetylcysteine L-lysinate metered dose inhaler in dogs: airways epithelial function changes. Eur Respir J 1994; 7: 81-87.
24. 24. App E M, Tomkiewicz R P, King M, Hochstrasser K, Schwaiblmair M, Fruhmann G, Coffiner M, Fossion J, Maes M. Thio-group carrying mucolytic agents inactivate proteases such as human neutrophil elastase (HNE) in vitro. Am Rev Respir Dis 1993; 147: A673.
25. 25. App E M, Baran D, Dab I, Malfroot A, Coffiner M, Maes P, Vanderbist F, King M. Efficacy, safety and tolerability of chronic inhalation therapy with nacystelyn versus placebo in cystic fibrosis patients. Am J Respir Crit Care Med 1997; 155: A199.
26. 26. App E M, Baran D, Tomkiewicz R P, Hochstrasser K, Coffiner J, Fossion J, Maes P, King M. A pilot study of an aerosolized new mucolytic agent nacystelyn (NAL) for the treatment of lung disease in cystic fibrosis. Am J Respir Crit Care Med 1994; 149: A676.
27. 27. Hardy J G, Everard M L, Coffiner M, Fossion J. Lung deposition of a nacystelyn metered dose inhaler formulation. J Aerosol Med 1993; 6: 37-44.
28. 28. Flodin N W. The metabolic roles, pharmacology, and toxicology of lysine. J Am Coll Nutr 1997; 16: 7-21.
29. 29. Mira M L, Silva M M, Manso C F. The scavenging of oxygen free radicals by angiotensin converting enzyme inhibitors: the importance of the sulfhydryl group in the chemical structure of the compounds. Ann N Y Acad Sci 1994; 723: 439-441.
30. 30. Zhang Y, Betts W H, Rokicinski M, Horowitz J D. N-Acetylcysteine scavenges free radicals produced by human neutrophils. Clin Exp Pharmacol Physiol 1991; Suppl 18: 69.
31. 31. Kharazmi A, Nielsen H, Schiotz P O. N-Acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int J Immunopharmac 1988; 10: 39-46.
32. 32. Aruoma O I, Akanmu D, Cecchini R, Halliwell B. Evaluation of the ability of the angiotensin-converting enzyme inhibitor captopril to scavenge reactive oxygen species. Chem Biol Interactions 1991; 77: 303-314.
33. 33. Chopra M, Beswick H, Clapperton M, Dargie H J, Smith W E, McMurray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent but lipid peroxidation is inhibited by both sulfhydryl-and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330-340.
34. 34. Ginsburg I, Misgav R, Gibbs D F, Varani J, Kohen R. Chemiluminescence in activated human neutrophils: role of buffers scavengers. Inflammation 1993; 17: 227-243.
35. 35. Clapperton M, Beswick P H, Abdullah I, Dargie H J, Fisher A C, McMurray J. Effect of captopril, enalaprilat and mercaptopropionyl glycine (MPG) on the oxidative activity of isolated neutrophils. Br J Clin Pharmacol 1995; 40: 31-35.
36. 36. Moldeus P, Cotgreave I A, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986; 50: 31-42.
37. 37. Cuperus R A, Muijsers A O, Wever R. Antiarthritic drugs containing thiol groups scavenge hypochlorite and inhibits its formation by myeloperoxydase from human leukocytes. A therapeutic mechanism of these drugs in rheumatoid arthritics? Arthr Rheumat 1985; 28: 1228-1233.
38. 38. van Herwaarden C L A, Bast A, Dekhuijzen P N R. The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease. Netherlands J Med 1995; 47: 45-48.
39. 39. Bagchi D, Prasad R, Das D K. Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem Biophys Res Commun 1989; 158: 52-57.
40. 40. Johansson A, Jesaitis A J, Lundqvist H, Magnusson K E, Sjolin C, Karlsson A, Dahlgren C. Different subcellular localization of cytochrome b and the dormant NADPH-oxidase in neutrophils and macrophages: effect on the production of reactive oxygen species during phagocytosis. Cell Immunol 1995; 161: 61-71.